A Discussion with Leonard Wartofsky,MD: Teacher,Clinician,Investigator,Mentor of Many,a Medical Politician,and Guest Editor of Thyroid Volume 1 Number 1
Restricted accessResearch articleFirst published online December, 2023
A Discussion with Leonard Wartofsky,MD: Teacher,Clinician,Investigator,Mentor of Many,a Medical Politician,and Guest Editor of Thyroid Volume 1 Number 1
DaviesTF. The scientific contributions of Martin Surks, MD, MACP: A pioneer in thyroid hormone physiology, subclinical hypothyroidism, and endocrine education. Thyroid, 2022; 32(7):745–749.
2.
McKenzieJM. A thyroid-stimulating life: An interview with Dr. J. Maxwell McKenzie. Thyroid, 2001; 11(11):1035–1042.
3.
DaviesTF. Braverman's thyroid—An interview with Lewis Braverman. Thyroid, 2005; 15:188–196.
4.
DaviesTF. Growing an interest in autoimmune thyroid disease—An interview with Robert Volpe MD. Endocrinol Metab Clin North Am, 2000; 29(2):431–442.
5.
DaviesTF. The active times of Jerome Hershman, MD: An Interview with the Founding Editor of Thyroid About a Life Devoted to the Thyroid Gland (and Other Things). Thyroid, 2021; 31(11):1609–1612.
6.
RitchieDA.Doing Oral History: A Practical Guide: Oxford University Press: New York, NY, USA; 2003.
7.
WartofskyL, RansilBJ, IngbarSH. Inhibition by iodine of the release of thyroxine from the thyroid glands of patients with thyrotoxicosis. J Clin Invest, 1970; 49(1):78–86.
8.
TramontanoD, CushingGW, MosesAC, IngbarSH. Insulin-like growth factor-I stimulates the growth of rat thyroid cells in culture and synergizes the stimulation of DNA synthesis induced by TSH and Graves’-IgG. Endocrinology, 1986; 119:940–942.
9.
WartofskyL, EarllJM. Non-thyroxine iodine release from the thyroid during acute malaria. J Clin Endocrinol Metab, 1972; 35(4):624–626.
10.
WartofskyL, MartinD, EarllJM. Alterations in thyroid iodine release and the peripheral metabolism of thyroxine during acute falciparum malaria in man. J Clin Invest, 1972; 51(9):2215–2232.
BurmanKD, BongiovanniR, GarisRK, et al.Measurement of serum T4 concentration by high performance liquid chromatography. J Clin Endocrinol Metab, 1981; 53(5):909–912.
13.
BurmanKD, YeagerHC, BriggsWA, et al.Resin hemoperfusion: A method of removing circulating thyroid hormones. J Clin Endocrinol Metab, 1976; 42(1):70–78.
14.
BoehmTM, McLainJ, BurmanKD, et al.Iodine treatment of iodine-induced thyrotoxicosis. J Endocrinol Invest, 1980; 3(4):419–424.
15.
BoehmTM, BurmanKD, BarnesS, et al.Lithium and iodine combination therapy for thyrotoxicosis. Acta Endocrinol (Copenh), 1980; 94(2):174–183.
16.
Van NostrandD, AtkinsF, YeganehF, et al.Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma. Thyroid, 2002; 12(2):121–134.
17.
Van NostrandD, MoreauS, BandaruVV, et al.(124)I positron emission tomography versus (131)I planar imaging in the identification of residual thyroid tissue and/or metastasis in patients who have well-differentiated thyroid cancer. Thyroid, 2010; 20(8):879–883.
18.
WuD, Gomes-LimaCJ, KulkarniK, et al.30 mCi exploratory scan for two-step dosimetric (131)I therapy in differentiated thyroid cancer patients: A novel approach and case report. World J Nucl Med, 2020; 19(3):266–270.
19.
WuD, YlliD, Gomes LimaCJ, et al.Use of (99m)Tc-sestamibi SPECT/CT when conventional imaging studies are negative for localizing suspected recurrence in differentiated thyroid cancer: A method and a lesson for clinical management. Endocrine, 2018; 62(1):57–63.
20.
ShobabL, Gomes-LimaC, ZeymoA, et al.Clinical, pathological, and molecular profiling of radioactive iodine refractory differentiated thyroid cancer. Thyroid, 2019; 29(9):1262–1268.
21.
ShobabL, WartofskyL. Perspective: The molecular landscape of radioactive iodine refractory differentiated thyroid cancer and poorly differentiated thyroid cancer. Thyroid, 2023; 33(2):138–142.
22.
HershmanJM, EdwardsCL. Serum thyrotropin (TSH) levels after thyroid ablation compared with TSH levels after exogenous bovine TSH: Implications for 131-I treatment of thyroid carcinoma. J Clin Endocrinol Metab, 1972; 34(5):814–818.
23.
NoelGL, DimondRC, WartofskyL, et al.Studies of prolactin and TSH secretion by continuous infusion of small amounts of thyrotropin-releasing hormone (TRH). J Clin Endocrinol Metab, 1974; 39(1):6–17.
24.
Van NostrandD, KhorjekarGR, O'NeilJ, et al.Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in the identification of metastasis in differentiated thyroid cancer with 131I planar whole-body imaging and 124I PET. J Nucl Med, 2012; 53(3):359–362.
25.
HaugenBR, PaciniF, ReinersC, et al.A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab, 1999; 84(11):3877–3885.
26.
DaviesTF. Analysis of the results of phase III controlled clinical trials with recombinant human thyrotropin: Developing a clinical guide. Endocr Pract, 2000; 6(5):391–395.
